masthead-publications

Categories

Filter by Topics

ABC-DLBCL ADCC Gene Alteration Airway Remodeling AKT Targeted Therapy ALK Alleles Angiogenesis Anti-TNF Alpha Therapy Anus Apoptosis AR-Specific T Cells Asthma Autocrine Signaling Autoimmune Disorder AXL B-cell lines B-cell lymphoma Biofluid Biology of neoplasia Biomarker Biomarker Analysis Biomarker Discovery Biomarker Patient Stratification Biomarker Validation Biomarkers Biomarkers Outcome Bladder Bladder Cancer blood Brain Brain RNA Breast Breast Cancer Cancer Immune Response Carcinoma Cardio Vascular Disease cardiovascular disease CD-19 CD44 CDKN2A mutation Cell line Cells Cerebral Spinal Fluid Checkpoint Inhibitors Chemoresistance Chronic Obstructive Pulmonary Disease Circulating miRNAs Circulating Tumor Cells Classification Clinical Outcome Prediction Clinical Trials cMET Coccidioidomycosis Colon Colon cancer Colorectal cancer Comparative Approach Comparative Study Comparison study Comprehensive Gene Expression Study Cord Blood Buffy Coat Core Needle Biopsy Custom mRNA Cyclin E mRNA Cytokines Detection Developmental Immunotherapy Diabetes Diagnostic Biomarkers Differential Diagnosis Differential Expression Differential Gene Expression Analysis Diffuse large B-cell lymphoma Dissecting Genomic Biomarkers DLBCL Drug Response Drug Safety Drug Targets Drug-induced Liver Injury Efficacy EGFR Muatations EMT EMT-mediated resistance Encephalophy Epidemiology outcomes Epigenetics Epigenomic Epstein-Barr ERBB2 Esophageal Cancer Exosomes Extracellular Vesicles Extracted RNA Fabry Disease Feasibility FFPE FFPE Canine Tumor FGF Ligand Trap FGFR Fibrous Tumors Gastrointestinal Cancers Gene Expression Analysis Gene Expression Comparisons Gene Expression Profiling Gene Expression Signatures Gene Fusions Gene Pathway Analysis Genetic Polymorphism Genomic Genomic Bioinformatics Head and Neck Cancer Heart HER2 Histone Deacetylase Inhibitors HTG EdgeSeq HTG EdgeSeq ALKPlus Assay EU HTG EdgeSeq DLBCL Cell of Origin Assay HTG EdgeSeq DLBCL Cell of Origin Assay EU HTG EdgeSeq EGFR KRAS and BRAF Mutation Assay HTG EdgeSeq Immuno-Oncology Assay HTG EdgeSeq miRNA Whole Transcriptome Assay HTG EdgeSeq Mouse mRNA Tumor Response Panel HTG EdgeSeq Oncology Biomarker Panel HTG EdgeSeq Precision Immuno-Oncology Panel HTG EdgeSeq System HTG EdgeSeq System Oncology Biomarker Panel Human Human serum Hypoxia Immune Immune Checkpoint Inhibitors Immune Related Genes Immune Response Immune Tolerance Immune-checkpoint blockade Immune-related Colitis Immuno-Oncology Immunofluorescence Immunology Immunotherapy Induction Chemotherapy Inflammation Inflammatory Signatures Interferon Gamma Signature Invasive Breast Carcinoma Juvenile Arthritis Kidney Liposarcoma Liquid Biopsy Liver Lung Lung Adenocarcinoma Lung cancer Lung Carcinoma Lupus Lymph Node Metastasis Lymphoma Mechanism of Action Melanoma Mesothelioma MET Metastatic Colon Cancer Metastatic Prostate Cancer Methods Comparison Mice Mice PDX Microenvironment miRNA miRNA WTA miRQC study Molecular Characterization Mouse Mouse mRNA mRNA mRNA custom mRNA expression in tumors mTOR pathway mTORC1 mTORC2 Mucin Hypersecretion Multiple Myeloma Muscle Mutations MYC Myocardial Reperfusion Myocarditis NAFLD Nash and Fibrosis Natural Killer Cells Neoantigens Neuroendocrine Tumor Nivolumab non-Hodgkin Lymphoma Non-small Cell Lung Cancer Novel Therapeutic Targets NSCLC NTRK1 Oesophageal Adenocarcinoma Oncogenes Oncology Oncomirs Oral Cancer Oral Squamous Cell Carcinoma Osteoclast Ovarian cancer Overexpression P13KmTOR Inhibitor Palbociclib Pancreas Pancreatic Cancer Pancreatic Ductal Adenocarcinoma Pancreatic ductal adenocarcinoma Paralysis Parkinson's Disease Pathogenesis Pathology Pathway Analysis Pathways PCA Cell Lines PD-1 PD-L1 Pd-L1 Phase 3 clinical trial PI3K signaling pathway PIK3CA mutation Plasma plasma Platform Comparison Pralatrexate predictive Predictive Biomarkers Predictive Modeling Pro-inflammatory cytokines Profiling Profiling Signature Development Prognostic Prognostic Biomarkers Programmed cell death protein 1 Programmed death ligand 1 Progression free-survival Prostate Prostate Cancer qNPA qPCR Radiation Toxicities Radioimmunotherapy Rearrangements rectum Regulation Renal Cell Carcinoma Renal Disease Responders vs Non-responders Response rate RET Reveal Rheumatoid Arthritis Risk Score Rituximab ROS1 safety Sarcoidosis Sarcoma SCBC SCLC Serum Signaling Inhibitors Signaling Pathways Signature Development Signature Pathway Analysis Signature Validation Signatures Sinonasal Undifferentiated Carcinoma Skin Small bowel Small Cell Bladder Cancer Small cell bladder cancer Small Cell Lung Cancer SPECS Lung Consortium Squamous cell carcinoma Sub-typing Surveillance Survival Outcomes Survival plots Synovial Fluid System Validation Systemic Lupus Erythematousus T cell T-cells Technology Comparison Therapeutic Response Therapeutic targets Tissue-based biomarkers TMB Toxicity TP53 mutation Translational Medicine Transplantation Treatment Outcome Treatment Stratification Treatment Targets Triple Negative Breast Cancer Tumor Biology Tumor Heterogeneity Tumor Immunobiology Tumor infiltrating lymphocytes tumor mutational burden Tumor Mutational Burden Type 1 diabetes Urothelial carcinoma Uveal melanoma VEGFR Venetoclas Vistusertib WNT Path Signaling Xenograft Tissue

2020

2019

2018

Pazopanib for treatment of advanced malignant and dedifferentiated solitary fibrous tumour: a multicentre, single-arm, phase 2 trial

Martin-Broto, J., et al.  Pazopanib for treatment of advanced malignant and dedifferentiated solitary fibrous tumour: a multicentre, single-arm, phase 2 trial. Lancet Oncol 2018 Dec. http://dx.doi.org/10.1016/S1470-2045(18)30676-4

Download pdf 1.0MB

Characterization of the immune tumor microenvironment (TME) to inform personalized medicine with immuno-oncology (IO) combinations

Luke J., et al. Characterization of the immune tumor microenvironment (TME) to inform personalized medicine with immuno-oncology (IO) combinations. Poster session presented at: ESMO 2018 Congress. Annals of Oncology (2018) 29 (suppl_8): viii400-viii441. 10.1093/annonc/mdy288

View External Link

Gene expression difference (GED) revealed immune function gene down-regulation as tumor-associated inflammatory cell (TAIC) infiltration in microenvironment in non-small cell lung cancer (NSCLC)

Wistuba, I., et al, Gene expression difference (GED) revealed immune function gene down-regulation as tumor-associated inflammatory cell (TAIC) infiltration in microenvironment in non-small cell lung cancer (NSCLC). Poster#4054 Presented at American Association for Cancer Research (AACR) Annual Meeting; 2018 Apr 14-18; Chicago, IL

Download ppt 1.9MB
View External Link

Fibroblast growth factor receptor 3 (FGFR3), peroxisome proliferator-activated receptor gamma (PPARg), and outcomes with nivolumab (nivo) in metastatic urothelial cancer (UC).

Galsky, M. et al. Fibroblast growth factor receptor 3 (FGFR3), peroxisome proliferator-activated receptor gamma (PPARg), and outcomes with nivolumab (nivo) in metastatic urothelial cancer (UC). Poster session presented at: Genitourniary Cancers Symposium; 2018 Feb 9; San Francisco, CA. J Clin Oncol 36, 2018 (suppl 6S; abstr 511).

View External Link

2017

Analysis of Expression of Immunomodulation Factors in Alveolar Soft-Part Sarcoma: A Retrospective Study from the Spanish Group for Research on Sarcoma

Hindi, N., et. al.,  Analysis of Expression of Immunomodulation Factors in Alveolar Soft-Part Sarcoma: A Retrospective Study from the Spanish Group for Research on Sarcoma. Poster presented at European Society for Medical Oncology (ESMO). 2017 Sept 8 - 12; Madrid, Spain.

Download pdf 526KB

Advanced molecular characterization of severe autoimmune toxicities associated with checkpoint inhibitor therapies

Balko J., et al. Advanced molecular characterization of severe autoimmune toxicities associated with checkpoint inhibitor therapies. Poster session presented at: The American Association for Cancer Research, 2017 Apr; Washington, DC

Download pdf 1.1MB

Heterogeneity in immune biomarker expression after acquisition of resistance to EGFR kirase inhibitors: Analysis of a case with small cell lung cancer transformation

Suda et. al. Heterogeneity in immune biomarker expression after acquisition of resistance to EGFR kirase inhibitors: Analysis of a case with small cell lung cancer transformation; J Thorac Oncol. 2017 Jun; 1216: 1015 

View External Link

A Cross Comparison of Technologies for the Detection of Immune System Related Gene Expression Signatures in Clinical FFPE Samples of Metastatic Prostate Cancer Patients

Howard K., et al. A Cross Comparison of Technologies for the Detection of Immune System Related Gene Expression Signatures in Clinical FFPE Samples of Metastatic Prostate Cancer Patients.  Poster session presented at: The American Association of Cancer Research 2017 Apr; Washington, DC.

Download pdf 2.2MB

Page last updated March 10, 2020